Introduction
In real-life clinical practice, scientific evidence alone is insufficient; experience is required to apply the scientific knowledge to the individual patient in a balanced manner, weighing the benefits and risks to the patient.
For patients with benign prostatic hyperplasia (BPH)/male lower urinary tract symptoms (LUTS), there are many treatment modalities, from conservative watchful waiting to medications and surgical procedures. Each modality has its own risk and benefits. Decision-making would depend on the severity of the disease, and each individual patient's age, comorbidity and preferences. The top priority for treating any disease is to save lives; for example, when solid organs are ruptured in trauma. In clinical BPH, sepsis with chronic obstruction can be life-threatening, though it is not common. The second priority is to preserve organ functions. The concerns in clinical BPH are the bladder functions of storage and voiding. Chronic obstruction can also lead to back pressure changes with the development of hydronephrosis, affecting kidney functions. Third, treatment is given to relieve symptoms. Whether treatment is necessary for symptomatic relief depends on the degree of bother to the patient. In this situation, the patient and not the physician is the best person to decide on the treatment, underscoring the importance of patient preferences and values in decision-making.
Definition of clinical BPH
Clinical BPH can be defined as prostate adenoma/adenomata (PA) irrespective of size, causing varying degrees of obstruction with or without symptoms. 1 With this definition, clinical BPH can be differentiated from other causes of male LUTS and managed appropriately.
PA can be diagnosed non-invasively in the clinic with transabdominal ultrasound, measuring prostate volume and intravesical prostatic protrusion (IPP). IPP is the distance from the innermost protrusion of the prostate to the base, at the circumference of the bladder. It is graded accordingly: grade 1: ≤5 mm; grade 2: >5-10 mm; and grade 3: >10 mm 2 . IPP can be considered as the shape of the prostate, distorting the funnelling effect of the bladder outlet and causing obstruction.
Predicting progression of disease for individualized care
Clinical BPH is a progressive disease, but one that worsens slowly over the years. 3 IPP helps to predict obstruction and disease progression. In our study of 200 patients, 94% of grade 3 IPP patients were obstructed compared with 21% of grade 1 IPP patients. 4 In another study on 259 patients with mean follow-up time of 32 months, the progression rate was 6% for patients with grade 1 IPP versus 44% for patients with grade 3 IPP. 5 However, management of PA should not be based on IPP alone, as the other 56% of patients did not deteriorate. For more complete individualized care, apart from IPP, management should be according to the severity of the disease.
The severity can be classified using our staging system, which is based on the presence or absence of bothersome symptoms and significant obstruction affecting functions of the bladder or kidneys, as shown in Table 1 . 6 Usually there is good concordance between stage and grade; only a minority of patients (16%) with discordance would require further more invasive tests, such as urodynamic studies or flexible cystoscopy. 7 
Conclusion
With this classification, treatment of PA can be individualized and tailored accordingly. Final decision-making would be personalized to the patient's age, comorbidity and preferences (values). This would be in line with the recent emphasis on patient-centered care in evidence-balanced medicine, treating the patient not just the disease. 8, 9 Editorial Comment Editorial Comment to From evidence-based medicine to evidence-balanced medicine for individualized and personalized care: As applied to benign prostatic hyperplasia/ male lower urinary tract symptoms
The article by Foo discusses the current status of evidencebased medicine for the management of benign prostate hyperplasia (BPH) and male lower urinary tract symptoms (LUTS). 1 The author might think most urologists or physicians treat these common conditions based on their own experience or past practice rather than taking an evidencebased approach. As BPH and LUTS are generally benign, therapeutic decision-making often takes how the patients feel or patient preferences into account. In fact, however, most physicians or urologists routinely evaluate the subjective severity of BPH/LUTS using validated tools, such as the International Prostate Symptom Score/Quality of Life questionnaires, before initiation of the therapy, along with clinical measures such as post-void residual urine volume and uroflowmetry, and use combined data for decision-making. However, no definitive scoring system linking indications to therapies has been well-established so far.
The present study by Foo proposes using the intravesical prostatic protrusion (IPP) degree and the presenting severity for staging therapeutic strategies for BPH/LUTS based on evidence-balanced medicine for individualized and personalized care. 1 The IPP is a comparatively recent tool, but several authors have pointed out the efficacy of this new index for evaluating the severity of BPH/LUTS as well as for post- 
